3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Tumor-Agnostic
3
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
98
daratumumab
57
Lenalidomide
53
Bortezomib
38
pomalidomide
37
Cyclophosphamide
37
carfilzomib
25
Calcium Dobesilate
25
fludarabine
22
talquetamab
19
iberdomide
18
isatuximab
17
Specimen Handling
17
Magnetic Resonance Spectroscopy
17
Biopsy
15
selinexor
13
dexamethasone acetate
12
belantamab mafodotin
12
Melphalan
12
dexamethasone 21-phosphate
11
auricularum
10
venetoclax
8
fludarabine phosphate
7
elotuzumab
7
X-Rays
6
tocilizumab
5
Blood Specimen Collection
5
ruxolitinib
4
ixazomib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Erlotinib Hydrochloride
×
Plasma cell
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled